Synthesized oligosaccharide, which is the active component of innovative vaccine

In chemistry lab glycoconjugates Zelinsky Institute headed Corr. RAS Nicholas E. Nifant’eva was synthesized unique oligosaccharide, which is an active component of innovative vaccines.

Vaccine, the effect of which was studied at Harvard Medical School, can be used to combat Staphylococcus aureus and other dangerous bacteria, fungi, and protozoa.

The results were published in the journal «Proceedings of the National Academy of Sciences of the United States of America, 2013, may, doi: 10.1073/pnas.1303573110," Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens".

Professional community assessed the results as a breakthrough in the protection from exposure to dangerous pathogens. Congratulations on the success of our colleagues who participated in this work: Nicholas Nifant’eva, Yuri Tsvetkov, Marina Gening.